The U.S. Centers for Medicare & Medicaid Services has selected three Pfizer-branded therapies—Xeljanz, Cibinqo and Inlyta—for the third cycle of the Medicare Drug Price Negotiation Program. These products, which collectively generated more than $7.2 billion in U.S. sales last year, will enter formal price talks beginning this summer. This is Pfizer’s first exposure of Part B–paid oncology agent Inlyta to mandatory negotiation, potentially pressuring its current average sale price of $66,000 per patient per year. Investors should model a 15–25% reduction in negotiated prices, based on precedents from the second-cycle negotiations, which could shave $500 million to $1 billion off annual revenues if implemented in 2028 contracts.

Analyst consensus projects Pfizer’s fourth-quarter revenue to decline by 4–6% year-over-year, driven by waning demand for COVID-19 products and the patent expiration of key cardiovascular franchise Lipitor. Non-COVID vaccine sales are expected to grow modestly—by roughly 3%—supported by rollout of the RSV vaccine in adults, but this will not fully offset a forecasted $1.2 billion drop in COVID-19 booster sales. Adjusted operating margin is forecast at 32–34%, down from 35% a year earlier, reflecting higher clinical expense in late‐stage immunology trials and continued investments in novel oncology and rare disease pipelines.

Over the past six months, Pfizer’s total shareholder return has lagged both Merck and Johnson & Johnson by approximately 12 percentage points. This underperformance stems primarily from the upcoming 2026 patent cliff on its blockbuster oncology agent Bavencio, combined with guidance for flat-to-mid single-digit revenue growth next year. In contrast, Merck’s Keytruda and J&J’s immunology biologics portfolios enjoy patent protection through at least 2028. Investors may reallocate capital until Pfizer demonstrates new growth drivers—such as gene-editing candidate VRTX-101 in phase 2 or its AZ-licensed RSV vaccine achieving broader pediatric approvals.

Despite proposed global price parity reforms, Pfizer secured a three-year exemption from the administration’s Section 232 import tariffs, shielding its U.S. operations from sudden cost pressure through 2027. Additionally, the planned overhaul of pharmacy benefit manager rebates could advantage Pfizer’s direct-to-consumer Oral Solid dose portfolio—estimated at $15 billion in annual revenue—by removing opaque rebate clawbacks. Market strategists now view the launch of TrumpRx.gov, which facilitates bulk government purchasing of outpatient medicines, as a volume opportunity rather than a revenue threat for Pfizer’s top‐selling oral therapies.